Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 603 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR What Are Patient-Reported Outcomes and Why Are They Important in Cancer... June 29, 2023 Is Proton Therapy Safer than Traditional Radiation? February 11, 2020 How to Stay Healthy After Cancer October 28, 2020 31-Year Breast Cancer Survivor Celebrates 100th Birthday with Drive-By Mardi Gras... December 29, 2020 Load more HOT NEWS 10 Ways to Provide Support During Breast Cancer Awareness Month Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours What Cancer Caregivers Should Know About Hospice Care at Home: A... Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk...
